RxDoctor Payments Data

Waddah Allaf, MD

Pulmonary Disease · North Miami Beach, FLNPI 1386607836

Payments from drug & device makers

$29,301in general payments, 2019–2025

Across 253 payments — averaging $115.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$23K
  • GSK$2K
  • AstraZeneca$1K
  • ANI Pharmaceuticals, Inc.$585
  • Mallinckrodt Hospital Products Inc.$560
  • Boehringer Ingelheim$290
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$6,42598%
  • Education$1262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,301 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$551,159
Medicare patients
783
Services billed
6,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter803$550,438
Breztri AerosphereBudesonide/Glycopyr/Formoterol162$102,258
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr186$88,130
Breo ElliptaFluticasone/Vilanterol204$86,332
Spiriva RespimatTiotropium Bromide132$65,860
SymbicortBudesonide/Formoterol Fumarate220$55,310
Atrovent HfaIpratropium Bromide83$37,353
Stiolto RespimatTiotropium Br/Olodaterol Hcl79$37,078
Combivent RespimatIpratropium/Albuterol Sulfate74$35,284
Flovent HfaFluticasone Propionate74$31,461
EliquisApixaban36$16,434
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$6,712
Albuterol Sulfate HfaAlbuterol Sulfate251$6,115
BreynaBudesonide/Formoterol Fumarate34$3,938
Divalproex Sodium16$3,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,387$724,9001,193 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,336$164,281396 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$290$138,222285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →